5-Hydroxytryptamine (5-HT) agonists: Effects on neocortical slow wave activity after combined muscarinic and serotonergic blockade

Brain Research

Volumn 728, Issue 2, 1996, Pages 181-187

  Dringenberg, Hans C ^a   Vanderwolf, C H ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

5 HT agonist; 5 HT receptor; Electrocorticogram; Low voltage fast activity; Neocortex; Serotonin (5 HT)

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; BUSPIRONE; MUSCARINIC RECEPTOR BLOCKING AGENT; PARGYLINE; QUIPAZINE; RESERPINE; SCOPOLAMINE; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; ELECTROCORTICOGRAPHY; ELECTROPHYSIOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM;

EID: 0030605857     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00396-4     Document Type: Article

References (33)

1. [1] Azmitia, E.C. and Segal, M., An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat, J. Comp. Neurol, 179 (1978) 641-668.
2. 2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone, Eur. J. Pharmacol., 147 (1988) 343-350.
3. [3] Buzsaki, G., Bickford, R.G., Ponomareff, G., Thal, L., Mandel, R. and Gage, F.H., Nucleus basalis and thalamic control of neocortical activity in the freely moving rat, J. Neurosci., 8 (1988) 4007-4026.
4. [4] Cooky, R.K. and Vanderwolf C.H., Construction of wire leads and electrodes for use in slow wave recording in small animals, Brain Res. Bull., 3 (1978) 175-179.
5. [5] Dringenberg, H.C. and Vanderwolf, C.H., Some general anesthetics reduce serotonergic neocortical activation and enhance the action of serotonergic antagonists, Brain Res. Bull., 36 (1995) 285-292.
6. [6] Dringenberg, H.C., Vanderwolf, C.H. and Hamilton, J.T., Urethane reduces contraction to 5-hydroxytryptamine (5-HT) and enhances the action of the 5-HT antagonist ketanserin on the rat thoracic aortic ring, J. Neural Transm., 101 (1995) 183-192.
7. [7] Fuxe, K., Evidence for the existence of monoamine neurons in the central nervous system III, Z. Zellforsch., 65 (1965) 573-596.
8. [8] Glaser, T. and Traber, J., Buspirone: action on serotonergic receptors in calf hippocampus, Eur. J. Pharmacol., 88: (1983) 137-138.
9. 2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogs, J. Med. Chem., 29 (1986) 194-199.
10. [10] Green, A.R. and Backus, L.I., Animal models of serotonin behavior, Ann. N.Y. Acad. Sci., 600 (1990) 237-249.
11. [11] Hjorth, S. and Carlsson, A., Buspirone: effects on central monoaminergic transmission-possible relevance to animal experimental and clinical findings, Eur. J. Pharmacol., 83 (1982) 299-303.
12. [12] Humphrey, P.P.A., Hartig, P. and Hoyer, D., A proposed new nomenclature for 5-HT receptors, Trends Pharmacol. Sci., 14 (1993) 233-236.
13. 1A agonists on hippocampal rhythmical slow activity in unanesthetized rats, Neuropharmacology, 33 (1994) 905-914.
14. 3 receptors in rat brain using radioligand binding, Nature, 330 (1987) 746-748.
15. [15] McMillen, B.A., Buspirone and the dopaminergic system, In G. Tunnicliff, A.S. Eison and D.P. Taylor (Eds.), Buspirone: Mechanisms and Clinical Aspects, Academic Press, San Diego, 1991, pp. 163-176.
16. [16] Neuman, R.S. and Thompson, P.M., Serotonin mediates suppression of focal epileptiform activity induced by noxious stimulation, Epilepsia, 30 (1989) 307-313.
17. 2) receptors mediate enhancement of cortical unit activity, Can. J. Physiol. Pharmacol., 70 (1992) 1604-1609.
18. [18] Pazos, A. and Palacios, J.M., Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors, Brain Res., 346 (1985) 205-230.
19. 1C binding sites in rat frontal cortex, J. Neurochem., 41 (1986) 529-540.
20. [20] Peroutka, S.J., 5-Hydroxytryptamine receptor subtypes, Pharmacol. Toxicol., 67 (1990) 373-383.
21. 1A receptor in the rat brain: correlation with receptor binding, J. Neurosci., 12 (1992) 440-453.
22. [22] Riblet, L.A., Taylor, D.P., Eison, M.S. and Stanton, H.C., Pharmacology and neurochemistry of buspirone, J. Clin. Psychol., 43 (1982) 11-16.
23. 2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA), Eur. J. Pharmacol., 102 (1984) 23-29.
24. [24] Stewart, D.J., MacFabe, D.F. and Vanderwolf, C.H., Cholinergic activation of the electrocorticogram: role of the substantia innominata and effects of atropine and quinuclidinyl benzilate, Brain Res., 322 (1984) 219-232.
25. [25] Vandermaelen, C.P., Matheson, G.K., Wilderman, R.C. and Patterson, L.A., Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur. J. Pharmacol., 129 (1986) 123-130.
26. [26] Vanderwolf, C.H., Neocortical and hippocampal activation in relation to behavior: effects of atropine, eserine, phenothiazines, and amphetamine, J. Comp. Physiol Psychol., 88 (1975) 300-323.
27. [27] Vanderwolf, C.H., Aminergic control of the electrocorticogram: a progress report, In A.A. Boulton, G.B. Baker, W.G. Dewhurst and M. Sandler (Eds.), Neurobiology of the Trace Amines, Humana Press, Clifton, NJ, 1984, pp. 163-183.
28. [28] Vanderwolf, C.H., Cerebral activity and behavior: control by central cholinergic and serotonergic systems. Int. Rev. Neurobiol., 30 (1988) 225-340.
29. [29] Vanderwolf, C.H. and Baker, G.B., Evidence that serotonin mediates noncholinergic neocortical low voltage fast activity, noncholinergic hippocampal rhythmical slow activity and contributes to intelligent behavior, Brain Res., 374 (1986) 342-356.
30. [30] Vanderwolf, C.H., Baker, G.B. and Dickson, C.T., Serotonergic control of cerebral activity and behavior: models of dementia, Ann. NY Acad. Sci., 600 (1990) 366-383.
31. [31] Vanderwolf, C.H., Leung, L.-W.S., Baker, G.B. and Stewart, D.J., The role of serotonin in the control of cerebral activity: studies with intracerebral 5,7-dihydroxytryptamine, Brain Res., 504 (1989) 181-191.
32. [32] Vanderwolf, C.H. and Pappas, B.A., Reserpine abolishes movement-correlated atropine-resistant neocortical low voltage fast activity, Brain Res., 202 (1980) 79-94.
33. [33] Watson, N.V., Hargreaves, E.L., Penava, D., Eckel, L.A. and Vanderwolf, C.H., Serotonin-dependent cerebral activation: effects of methiothepin and other serotonergic antagonists, Brain Res., 597 (1992) 16-23.